Anthropic warns of ‘existential risks to humanity’ from AI; AstraZeneca makes $2bn cancer drug tie-up – business live
<p>Rolling coverage of the latest economic and financial news</p><p><strong>Pharmaceuticals news: AstraZeneca is investing $2bn in biopharmaceutical oncology company Summit Therapeutics, as part of a tie-up to jointly develop and test anti-cancer drugs.</strong></p><p>Announcing the deal, <strong>AstraZeneca </strong>says the two companies will collaborate on a series of studies testing their cancer treatments together.</p><p>“A core pillar of our oncology strategy is to broaden the reach of our ADC portfolio as the backbone of treatment across tumour types with combinations alongside next-generation immunotherapies.</p><p>Bispecifics targeting PD-1 and VEGF are rapidly advancing in development and have the potential to improve on current immunotherapies, particularly in lung, breast and gastrointestinal cancers. This opportunity to combine ivonescimab with AstraZeneca’s ADC portfolio, including with Sone-Ve, could enable new regimens that raise the bar for patients with cancer across the treatment landscape.”</p><p>“Our development of highly advanced models, platforms, and applications and expansion of use cases could further increase the risk that our models cause harm.”</p><p>“Potential model awareness of our evaluation efforts creates a significant limitation on our ability to assess model safety.”</p> <a href="https://www.theguardian.com/business/live/2026/sep/29/anthropic-ipo-warning-existential-risks-to-humanity-from-ai-astrazeneca-2bn-cancer-drug-tie-up-diesel-stock-market-live-news-updates">Continue reading...</a>
SOURCE: The Guardian ↗ · +1 more
What This Means
Anthropic, an AI safety-focused company, has included warnings about existential risks from artificial intelligence in its IPO prospectus, a standard regulatory disclosure document. The inclusion signals that the company views these risks as material enough to flag to potential investors, though such risk disclosures are common practice in IPO filings and do not necessarily indicate imminent threats. This could affect investor perception of AI sector valuations and risk appetite, particularly among funds with ESG or risk-management mandates, though the market impact depends on how broadly investors interpret the disclosure versus treating it as boilerplate risk language.
Markets since first report
Daily closes from the day before this was first reported to the latest close. Prices move for many reasons; shown for context, not as cause and effect.
Coverage · 2 sources
- The Guardian first reported it
- CNBC picked it up 2 hours later
Sources — 1 tier
Every claim below links directly to the original reporting it was drawn from. Penblock synthesizes and cross-references these sources — it doesn't originate the reporting.
How This Could Play Out — recorded when first flagged, not updated
Resolve
UNLIKELYIf regulatory bodies or industry coalitions respond to Anthropic's warning with concrete safety frameworks and disclosure standards, AI-focused infrastructure and software companies might face near-term compliance costs offset by longer-term investor confidence in managed risk—though such coordination typically takes years to materialize.
Left Unattended
LIKELYAnthropic's warning, treated as one company's risk disclosure among many similar statements in the sector, would likely have minimal sustained impact on AI hardware or software valuations, with market participants continuing to price in regulatory uncertainty as a background factor rather than a catalyst.
Escalate
POSSIBLEIf Anthropic's warning triggers legislative or institutional investor pressure for AI model restrictions, compute-intensive development timelines, or mandatory safety audits, this could create headwinds for semiconductor demand and AI infrastructure spending in the near term, though the mechanism would depend on the specificity and enforceability of any resulting policy.
SPONSORED
Confidence History
- MEDIUM CONFIDENCESep 29, 2026 at 7:02 AM
Single-tier claim only (mainstream) -- no independent corroboration yet